Lebozeck et al. reported the production and characterization of a humanized Fab fragment against GPVI, designated as ACT017(glenzocimab), which presented a high capacity to inhibit collagen-induced platelet aggregation ex vivo after injection, specifically (1–8 mg/kg, IC50: 3.2 ± 2.5 μg/mL) to the macaque without inducing thrombocytopenia, GPVI depletion, or bleeding side effects [105]. Here, GP6 is linked to Thrombocytopenia.